Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update
August 1, 2019 4:02 PM EDTStrong Crysvita® (burosumab) Launch Continues with Approximately 960 Patients on Reimbursed Commercial Therapy in the United States
Ultragenyx Submits New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
NOVATO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quarter ended June 30, 2019.
The U.S. launch of Crysvita continues to... More
